-

FUJIFILM Irvine Scientific to Exclusively Distribute Chemically Defined Substrate for Stem Cell Culture

Cellnest substrate enables optimal adhesion and proliferation of stem cells for cell and gene therapy research

SANTA ANA, Calif.--(BUSINESS WIRE)--FUJIFILM Irvine Scientific, Inc., today announced that it has become the exclusive, worldwide distributor of cellnest®, a recombinant peptide attachment substrate that provides optimal adhesion and proliferation of stem cells in chemically defined, animal component-free conditions. Cellnest was designed and manufactured by FUJIFILM Corporation, joining its vast portfolio of solutions that support life science applications and therapeutic innovation.

Attachment substrates mimic the extracellular matrix (ECM), a complex and dynamic environment in which cells reside in vivo, in cell culture and allow for the adhesion, expansion, and potential differentiation of stem cells. Unlike animal-derived components, which can introduce unpredictability in results, the chemically defined, animal component-free formula of cellnest provides consistent results to researchers, and can smooth the regulatory path to commercialization. Cellnest is compatible with any adherent cell type that binds to the Arg-Gly-Asp (RGD) domain, an amino acid sequence within the extracellular matrix protein fibronectin that mediates cell attachment. It is an ideal companion product to FUJIFILM Irvine Scientific’s PRIME-XV portfolio of xeno-free and chemically defined media for stem cell culture, and is well suited for the attachment and growth of mesenchymal stem cells (MSCs).

“We are dedicated to accelerating the development and introduction of new offerings, including cellnest, to support our partners in advancing cell and gene therapy research,” said Yutaka Yamaguchi, General Manager, Life Science Strategic Business Office, FUJIFILM Holdings America Corporation, and Chairman and CEO, FUJIFILM Irvine Scientific. “Leveraging the collective expertise and capabilities of our resources within the network of Fujifilm life science companies, enables us to provide innovative solutions for our partners, from discovery through to commercialization.”

For more information about cellnest, please visit: http://www.irvinesci.com/products/1063967-cellnest-recombinant-peptide

ENDS

Contacts

Media Contacts
Lorna Cuddon
Zyme Communications
Phone: +44 (0)7811996942
Email: lorna.cuddon@zymecommunications.com

FUJIFILM Irvine Scientific


Release Summary
FUJIFILM Irvine Scientific, Inc., today announced that it has become the exclusive, worldwide distributor of cellnest®
Release Versions

Contacts

Media Contacts
Lorna Cuddon
Zyme Communications
Phone: +44 (0)7811996942
Email: lorna.cuddon@zymecommunications.com

More News From FUJIFILM Irvine Scientific

CHITOSE and FUJIFILM Biosciences Form Strategic Alliance to Drive Global Innovation and Biopharmaceutical Manufacturing

KAWASAKI, Japan & SANTA ANA, Calif.--(BUSINESS WIRE)--Chitose Laboratory Corp., (CHITOSE), a leading company of the bioeconomy and provider of advanced cell line development services, and FUJIFILM Biosciences Inc., a global leader in the innovation and manufacture of cell culture solutions for the life science market, today announced a new strategic alliance that leverages the strengths of both companies in advancing biopharmaceutical production. CHITOSE’s expertise in cell line development usi...

FUJIFILM Biosciences Introduces BalanCD HEK293 Perfusion A Medium to Enable Gene Therapy Production

SANTA ANA, Calif.--(BUSINESS WIRE)--FUJIFILM Biosciences, a global leader in the innovation and manufacture of cell culture solutions for the Life Science market, today announced the commercial launch of BalanCD HEK293 Perfusion A. Designed to expand and augment the company’s portfolio of gene therapy application solutions, BalanCD HEK293 Perfusion A uses suspension HEK293 cells and perfusion technology to provide reliable, efficient, and scalable production of viral vectors for development of...

Fujifilm Rebrands Life Sciences Companies to Strengthen Position as Strategic Partners for Life, Offering End-to-End Solutions

TOKYO--(BUSINESS WIRE)--FUJIFILM Corporation's Life Sciences Group companies, a portfolio of businesses offering products, services and comprehensive solutions that span all stages of therapeutic development from discovery through to commercialization, today announced new names and identities as part of a strategic positioning effort. The Group Companies’ new names, collaborative strategic focus, and structural alignment reflects Fujifilm’s commitment to Life Sciences, offering fully integrated...
Back to Newsroom